摘要
目的观察拉米夫定治疗失代偿期乙肝肝硬化患者的疗效及安全性。方法回顾性分析2006年2月～2009年12月收治入院的80例失代偿期乙肝肝硬化患者临床资料,随机分为治疗组40例和对照组40例,治疗组给予口服拉米夫定100mg/d,52W,对照组不用抗病毒药物。在治疗前、后分别检测肝功能、HBV血清标志物、HBV-DNA、丙氨酸转氨酶(ALT),总胆红素(TBil),血清白蛋白(TLB),脱氧核糖核酸(DNA)及HbeAg血清学转换变化。结果治疗结束时,治疗组肝功能及HBV、DNA实验室指标的定量检测值及HBeAg血清学转换均较治疗前有明显改善(P<0.01)。结论拉米夫定能减轻失代偿期乙肝肝硬化患者的肝病严重程度。近期疗效显著,安全性好。可以作为抗HBV首选药物,尤其是终末期肝病患者应及早用药。
Objective To evaluate lamivudine therapy in patients with decompensated cirrhosis the efficacy and safety.Methods A retrospective analysis of our hospital in February 2006 -2009 admitted to hospital on Dec.80 cases of patients with decompensated cirrhosis clinical data of 40 patients were randomly divided into treatment group and control group of 40 patients,the treatment group received oral pull Mif given 100 mg / d,52 W,the control group without antiviral drugs.Treatment before and after liver function were detected,HBV serological markers,HBV-DNA,alanine aminotransferase （ALT）,total bilirubin （TBil）,serum albumin （TLB）,deoxyribonucleic acid （DNA） and HbeAg seroconversion change.Results After treatment,liver function and HBV,DNA testing laboratory values and quantitative indicators of HBeAg seroconversion than those before treatment significantly improved （P 0.01）.Conclusion ETV can reduce the decompensated liver cirrhosis in patients with severe degree.Recent significant effect,good security.Can be used as anti-HBV drug of choice,particularly in patients with end-stage liver disease should try medication.
出处
《当代医学》
2011年第13期65-66,共2页
Contemporary Medicine
